DREAMM-8 study: first results of BPd versus PVd in R/R myeloma

Suzanne Trudel, MSc, MD, University of Toronto, Princess Margaret Cancer Centre, Toronto, Canada, discusses the first findings of the DREAMM-8 study (NCT04484623), which compares belantamab mafodotin plus pomalidomide and dexamethasone (BPd) versus pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory (R/R) multiple myeloma (MM). The trial met its primary endpoint, with a progression-free survival (PFS) benefit observed in patients of all pre-specified subgroups receiving BPd. Overall survival (OS) data has not yet matured; however, a trend towards superior OS in the BPd group is currently seen. The safety profile of the BPd combination was manageable, and frequently observed ocular toxicities resolved following dose holds or reductions. Dr Trudel concludes that the BPd treatment regimen has shown robust efficacy and may provide an accessible off-the-shelf treatment option for patients with R/R myeloma. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.